About 270 Vision

Founded in 2011, 270 Vision are developers of simple-to-use, highly-accurate body analysis technology for use in injury prevention and rehabilitation in the medical, employee welfare and elite sports sectors.

With eight patents applied for, granted or pending internationally, including GB2530754 ‘Mapping the trajectory of a part of the anatomy of the human or animal body’, granted in May 2017 and GB2551238 ‘Mapping trajectories of the anatomy of the human or animal body for comparative analysis’ (Incidence Points) granted in March 2019, multi-award winning 270 Vision are internationally-renowned as the market leaders in motion sensor design and development, with Martin Gossling, Chief Executive Officer, frequently invited to speak at conferences.

Recognised for their work in the industry, the Founders of 270 Vision are Senior Associate Members of the Royal Society of Medicine. In 2018, 270 Vision won the prestigious Outstanding Achievement Award at the national Medilink UK Healthcare Business Awards, which celebrate outstanding innovative breakthroughs made in healthcare technology across the UK.

Having developed their advanced, medical-grade BPMpro sensor technology and undertaken commercial pilots with elite sporting organisations and orthopaedic surgeons, 270 Vision developed BPMpathway – the proven dimension in remote patient assessment in the critical weeks after orthopaedic surgery. BPMpathway was subsequently named Best Digital Health Platform in the 2018 Juniper Research Future Digital Awards.

Braun Melsungen AG, one of the world’s leading manufacturers of medical devices and pharmaceutical products and services have invested into 270 Vision as part of their strategy of securing access to key future technology. In addition to BPMpathway, 270 Vision are actively developing sensor-based solutions for employee welfare, elite sports, long-term medical care and other sectors.